A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1060 participants.
Also called NCT07931599
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,060 participants
- Sponsor
- Registry
-
NCT07931599
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Brazil, Bulgaria, China, Croatia, Hungary, Japan, Poland, Portugal, Saudi Arabia, Serbia, South Korea, Spain, Taiwan, United Kingdom
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07931599. Randomized; double masking; primary purpose treatment. Start 2026-11-10 (anticipated); primary completion 2028-07-24 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
- Acronym
- AMBITION4
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Zenagamtide
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo zenagamtide
- Intervention (Drug)
- Placebo semaglutide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct07931599- Content hash
d0698c0dc6cc8429dd1ea7d2a092c246464743ff34188d3bd2046f673a531324